DongKook Life Science

Total Valuation

DongKook Life Science carries a market capitalization of 79.64B, placing it among publicly traded companies globally. Its enterprise value stands at 176.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

DongKook Life Science currently has 31.98M shares outstanding.

Valuation Ratios

DongKook Life Science trades at a trailing price-to-earnings ratio of 16.64. The price-to-sales ratio is 1.13, and the price-to-book ratio stands at 2.37.

Enterprise Valuation

On an enterprise value basis, DongKook Life Science trades at an EV/EBITDA multiple of 13.16 and an EV/FCF ratio of 12.72. The EV/Sales ratio of 1.37 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 13.16 provides insight into valuation relative to core operating earnings.

Financial Position

DongKook Life Science maintains a current ratio of 1.71, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 29.39, indicating elevated leverage, while an interest coverage ratio of 4.58 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

DongKook Life Science posts a return on equity of 16.50 and a return on invested capital of 6.38.

Taxes

Over the trailing twelve months, DongKook Life Science has paid 2.11B in income taxes, reflecting an effective tax rate of 19.48.

Stock Price Statistics

DongKook Life Science's stock has declined approximately -71.80068% over the past 52 weeks. The 50-day moving average sits at 2,972.20, while the 200-day moving average is 3,495.78.

Income Statement

Over the trailing twelve months, DongKook Life Science generated 128.38B in revenue and converted that into 8.71B in net income, yielding earnings per share of 204.28. EBITDA reached 13.38B, while operating income came in at 13.38B.

Balance Sheet

DongKook Life Science holds 8.18B in cash and equivalents against 39.27B in total debt, resulting in a net debt position of 31.62B. Total book value stands at 61.17B, with working capital of 59.87B providing operational flexibility.

Cash Flow

DongKook Life Science produced 5.12B in operating cash flow over the past twelve months. After subtracting -6.37B in capital expenditures, free cash flow totaled -1.24B - equivalent to -29.15 per share.

Margins

DongKook Life Science operates with a gross margin of 26.33, reflecting its pricing power and cost economics. The operating margin of 10.42 and net profit margin of 6.79 provide insight into operational efficiency.

Dividends & Yields

Scores

DongKook Life Science posts an Altman Z-Score of 2.37, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.